These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 2568815)
1. Renal excretion and computed tomography enhancement of iotrolan and iopamidol in dogs. Benness G; Evill C; Wilcox J; Hassam R; Arozoo E Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():88-90. PubMed ID: 2568815 [TBL] [Abstract][Full Text] [Related]
2. Experimental urography in dogs: diagnostic quality and pharmacokinetic behavior of iotrolan in comparison to nonionic and ionic, monomeric contrast media. Nauert C; Mützel W Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():82-7. PubMed ID: 2568814 [TBL] [Abstract][Full Text] [Related]
3. [Experimental study on vascular permeability and hemodynamics of nonionic dimeric contrast media (Iotrolan): a comparison to nonionic monomer on dynamic CT and angiography]. Sako M; Sugimoto K; Hirota S; Matsumoto S; Kuwata Y; Hasegawa Y; Tomita M; Murakami T; Kono M Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Jan; 54(1):32-9. PubMed ID: 8121768 [TBL] [Abstract][Full Text] [Related]
4. Tissue distribution and excretion of iotrolan after intravenous and suboccipital injections in animals. Weinmann HJ; Scholz P; Mützel W Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():206-10. PubMed ID: 2568796 [TBL] [Abstract][Full Text] [Related]
5. [Preclinical evaluation of iotrolan as a contrast medium for angiography and urography]. Miyazawa T; Murayama C; Uchimoto R; Fritz-Zieroth B Nihon Igaku Hoshasen Gakkai Zasshi; 1992 Sep; 52(9):1287-98. PubMed ID: 1437534 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of iohexol, iopamidol, iopromide, and iosimide compared with meglumine diatrizoate. Hartwig P; Mützel W; Taenzer V Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():220-3. PubMed ID: 2568800 [TBL] [Abstract][Full Text] [Related]
7. Plasma level and renal excretion of iotrolan after lumbar injection in patients. Weinmann HJ; Vogelsang H; Mützel W; Speck U Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():224-7. PubMed ID: 2568801 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of iotrolan after intravenous injection into healthy volunteers. Scholz P; Weinmann HJ; Mützel W; Staks T Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():211-4. PubMed ID: 2568798 [TBL] [Abstract][Full Text] [Related]
9. [Iotrolan-300 versus Iopamidol-300 in hysterosalpingography]. Schulz-Wendtland R; Bauer M; Henne KW Aktuelle Radiol; 1991 Sep; 1(5):256-8. PubMed ID: 1751562 [TBL] [Abstract][Full Text] [Related]
10. [Clinical use of low osmolar roentgen contrast media]. Taenzer V Rontgenpraxis; 1984 Oct; 37(10):357-61. PubMed ID: 6505858 [No Abstract] [Full Text] [Related]
11. Clinical trials with iotrolan in myelographic and computed tomography applications in the United States. Goldstein HA; Pfennig D Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():167-70. PubMed ID: 2568788 [TBL] [Abstract][Full Text] [Related]
12. [Electron-beam tomographic imaging of the coronary arteries: an experimental comparison between monomeric and dimeric x-ray contrast media]. Taupitz M; Wagner S; Schuhmann-Giampieri G; Baumann S; Wolf KJ; Finke I; Hamm B Rofo; 1997 Jan; 166(1):3-7. PubMed ID: 9072100 [TBL] [Abstract][Full Text] [Related]
13. Does dilution of contrast media affect contrast enhancement? An experimental study in rats. Dean PB; Kivisaari L; Kormano M Invest Radiol; 1988 Sep; 23 Suppl 1():S118-21. PubMed ID: 3198330 [TBL] [Abstract][Full Text] [Related]
14. Examination of the nephrographic potential of iotrol by computed tomography. Evill CA; Wilcox J; Hassam RM; Benness GT; Arozoo E Invest Radiol; 1988 Mar; 23(3):216-20. PubMed ID: 3372182 [TBL] [Abstract][Full Text] [Related]
15. One or two samples for determination of total plasma clearance of a nonionic contrast medium in patients undergoing enhanced CT. Thomsen HS; Vestergaard A; Golman K; Dorph S Acta Radiol; 1992 Nov; 33(6):588-91. PubMed ID: 1449886 [TBL] [Abstract][Full Text] [Related]
16. Physicochemical properties and general pharmacology of the nonionic dimer iotrolan. Mützel W; Press WR; Weinmann HJ Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():28-32. PubMed ID: 2568804 [TBL] [Abstract][Full Text] [Related]
17. Chemistry, physicochemistry and pharmacology of known and new contrast media for angiography, urography and CT enhancement. Speck U; Mützel W; Weinmann HJ Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1983; 118():2-10. PubMed ID: 6139075 [No Abstract] [Full Text] [Related]
18. Urography with low-osmolality contrast media: comparative urinary excretion of Iopamidol, Hexabrix, and diatrizoate. Spataro RF; Fischer HW; Boylan L Invest Radiol; 1982; 17(5):494-500. PubMed ID: 7141831 [No Abstract] [Full Text] [Related]
19. Urine viscosity after injections of iotrolan or iomeprol. Ueda J; Furukawa T; Higashino K; Takahashi S; Araki Y; Kubo K; Nakashima T Acta Radiol; 1997 Nov; 38(6):1079-82. PubMed ID: 9394674 [TBL] [Abstract][Full Text] [Related]
20. CT-determined canine kidney and urine iodine concentration following intravenous administration of sodium diatrizoate, metrizamide, iopamidol, and sodium ioxaglate. Brennan RE; Rapoport S; Weinberg I; Pollack HM; Curtis JA Invest Radiol; 1982; 17(1):95-100. PubMed ID: 7076442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]